Method for differential organ preservation treatment of cervical pregnancy and pregnancy in uterine scar after caesarean section, depending on data of integrated ultrasound and levels of human chorionic gonadotropin (versions)

FIELD: medicine.

SUBSTANCE: after emergency hospitalization, bilateral embolization of the uterine arteries (UAE) is performed, including methotrexate administration of in the amount of 50 mg endoarterially in the presence of ultrasound signs of chorion infiltration with formation of vascular malformation and HCG level increase. The gestational sac is left. 3 days after, ultrasound and HCG control is performed. With a HCG decrease in by at least 25% and no visualization of blood flow in the chorion with ultrasound and colour Doppler mapping (CDM), the patient is released for outpatient monitoring. With blood flow persistence in the chorion, UAE is repeated with a search for these vessels. If there is insufficient decrease in the blood plasma HCG, the patient receives methotrexate into the gestational sac cavity in an amount of 2-10 mg. In the absence of ultrasound signs of chorionic growth, the gestational sac is removed simultaneously under the control of ultrasound. In the absence of bleeding and normal data of the control ultrasound after 1 day, the patient is released for outpatient monitoring. In the presence of ultrasound signs of chorionic ingrowth and decreasing level of HCG, UAE without endoarterial administration of methotrexate is performed. 3 days after, ultrasound and HCG control are performed. With a HCG decrease in by at least 10% and no visualization of blood flow in the chorion with ultrasound and CDM, the patient is released for outpatient monitoring.

EFFECT: maintaining the uterus integrity and its reproductive function while reducing the duration of hospitalization.

4 cl, 5 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: saliva of affected child is analysed by method of infrared spectroscopy, value of ratio of peak height with maximum at 1070 cm-1 to peak height with maximum 1025 cm-1 is calculated. If value of ratio is in range from 1.1 to 1.9 nonspecific ulcerative colitis is diagnosed, and if value of said ratio is from 2.0 to 4.6 Crohn's disease is diagnosed.

EFFECT: invention ensures less invasive and simpler differential diagnostic of NUC and Crohn's disease in children, ensures simplification and acceleration of diagnosis determination.

4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to a method of diagnosing bipolar affective disorder. The essence of the method consists in the fact that reliable differences in the spectrum of protein distribution in blood serum without proteins albumin, immunoglobulin G, immunoglobulin A, antitrypsin, transferin and haploglobin in patients with endogenic psychosis. If protein spots are detected on electrophoretic gel in areas with the molecular weight of 200, 84, 75, 49, 40 kDa in the patient with endogenic psychosis, bipolar affective disorder is diagnosed.

EFFECT: application of the claimed method makes it possible to increase accuracy in diagnostics being simple in realisation.

2 ex

FIELD: medicine.

SUBSTANCE: method involves determining female serum cytotoxicity to male lymphocytes, including a combined culture with reference male and analysed female serum in a 96-well tray in the presence of the nutrient medium RPMI 1640 in a CO2 incubator. One day later, lymphocytes are counted in the well in a Goryaev's chamber with the male (reference) and female (analysed) serum. That is followed by determining a cytotoxic index (CI), which represents a quotient of the analysed cell count and the reference cell count. The normal cytotoxic index makes approximately 0.7 and less.

EFFECT: invention enables studying the responses of female humoral immune factors to male antigens and evaluating a risk of miscarriage, early spontaneous abortions and missed miscarriages.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a high-sensitivity method for measuring the amount of individual's blood plasma glycyrrhizin, glycyrrhetinic acid and their pharmaceutically acceptable salts. The high-sensitivity method for measuring the amount of glycyrrhizin, glycyrrhetinic acid and their pharmaceutically acceptable salts is characterised by the fact that a mixture of individual's blood plasma with methanol or ammonia water in the specific concentration is introduced into a solid phase having the reverse-phase distribution function and the anion exchange function; the solid phase is then washed with a cleaning fluid that is a single-component fluid or a mixed fluid of at least two components specified in a group containing water, alkali, alcohol and acetonitrile. That is followed by elution from the solid phase in acid alcohol specified in formic acid - methanol or formic acid - ethanol; that is followed by the stage of measuring glycyrrhizin, glycyrrhetinic acid and their pharmaceutically acceptable salts by liquid chromatography - mass spectrometry or liquid chromatography - mass spectrometry/mass spectrometry.

EFFECT: high-sensitivity method enables detecting and measuring the amounts of individual's blood plasma glycyrrhizin, glycyrrhetinic acid and their pharmaceutically acceptable salts.

4 dwg, 17 tbl, 7 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises selection of only living, mature females of Trichuris vulpis from colon, blind gut of wild and/or domestic carnivorous animals infected spontaneously with whipworms in the study with helminthological methods when autopsy, into separate tubes with officinal isotonic solution (0.9%) of sodium chloride (solutio Natrii chlorati isotonica) and the exposure of the tubes with the females of Trichuris vulpis at t = 37.5-39°C for 5 hours under conditions of a thermostat.

EFFECT: method enables to select a large amount of fertilised eggs of T vulpis, not contaminated with particles of undigested feed, the particles of destroyed tissue of genitals of female of T vulpis and secondary bacterial microflora.

2 ex

FIELD: medicine.

SUBSTANCE: patient's peripheral venous blood is recovered to analyse genetic polymorphisms of coagulation factors VII 10976G/A FVII. A birth weight of a newborn of a woman delivering not for the first time in the stage of 37 and more weeks of pregnancy is determined by equation: y=6123.431-25.579x1+0.267x2+205.739x3, wherein y is an anticipated newborn's weight, x1 is a female's height in centimetres; x2 is an infant's weight at the previous delivery in grams, x3 is a genetic version of 10976G/A FVII locus with x3=1 for 10976 GG FVII genetic type, x3=2 for 10976 GA and 10976 AA FVII genetic types. A birth weight of a newborn of a woman delivering for the first time in the stage of 37 and more weeks of pregnancy is determined by equation: y=6278.037-21.739x1+232.170x2, wherein x1 is a female's height in centimetres; x2 is a genetic version of 10976G/A FVII locus with x2=1 for 10976 GG FVII locus, x2=2 for 10976 GA and 10976 AA FVII genetic types.

EFFECT: invention enables improving the prevention and treatment of the pregnancy complications.

2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: pre-operative fasting venous blood 1 ml is sampled at room temperature 20-24°C into an anticoagulant-free vacuum system (test tube). The test tubes are delivered in a sealed container at temperature 2-8°C for 2 hours to a laboratory for immunoenzyme assay and analysed to determine anti-thyroid stimulating hormone receptor antibodies. If the antibody level is 1.5 units/l or more, a thyroidectomy is performed, whereas the antibody level of less than 1.5 units/l requires performing a subtotal thyroid resection according to standard techniques.

EFFECT: invention enables reducing a probability of recurrent thyrotoxicosis in the patients after subtotal thyroid resection.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to a method for the prediction of a risk of early microvascular complications in the children suffering from type 1 diabetes mellitus. The substance of the method consists in defining a duration of the diseases in years, the patient's age in years, a desquamated endothelial cell count, high-density lipoprotein cholesterol, total cholesterol, triglycerides, atherogenic index, glycohaemoglobin, average daily glycaemic level; making a linear regression analysis and calculating a risk ratio (R) of early microvascular complications in the children suffering from type 1 diabetes mellitus by formula. If the risk ratio is ≥1, the high risk of early microvascular complications during one year is predicted; the ratio < 1 shows the low risk of microvascular complications during one year.

EFFECT: using the declared method enables increasing the prediction accuracy of microvascular complications in the children with type 1 diabetes mellitus.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and can be used for patient's status monitoring. A method for setting a time-varying physiological parameter warning signal involves patient's controlled parameter monitoring, comparing the controlled parameter to an initial cut-off criterion, varying the cut-off criterion temporarily by a cut-off criterion of deterioration after the therapy, and then after a certain period of time, by the cut-off criterion after the administration. The time allowed involves comparing the controlled parameter to the cut-off criterion of deterioration, and after the time allowed - to the cut-off criterion after the administration. The warning signal is initiated in response to the controlled parameter of one or more initial cut-off criteria, the cut-off criterion of deterioration and the cut-off criterion after the administration. The group of inventions also refers to a machine-readable carrier with software for implementing the method and to a system for user warning on the controlled parameter variation.

EFFECT: group of inventions provides higher accuracy and rate of assessing the patient's status according to the conducted therapy.

15 cl, 6 dwg

FIELD: medicine.

SUBSTANCE: invention can be used for the purpose of the early prediction of cystic periventricular leukomalacia (PVL) in the newborns with very low (VLBW) or extremely low body weight (ELBW). Substance of the method: the newborns with VLBW and ELBW on the 3rd-7th day of life are examined to assess the perinatal medical history, namely the presence of chorioamnionitis and amniotic fluid nature, 5th minute Apgar score, the absence of prolonged artificial pulmonary ventilation, a severity of respiratory distress syndrome, the presence of pneumonia, sepsis, convulsive disorder, anaemia, laboratory signs of the systemic inflammatory reaction, average values of carbon dioxide, anionic bicarbonate and base deficiency in capillary blood, interleukine-6 and receptor interleukine-1 antagonist in venous blood serum. Each sign is assigned with a prognostic coefficient (PC). That is followed by determining total PC, and it is expected cystic PVL that is decided for if total PC is at least (+)9.5, whereas no cystic PVL is expected if total PC is (-)9.5 or less.

EFFECT: invention provides the early (for the first 7 days of life) prediction of cystic periventricular leukomalacia in the most susceptible category of patients that are children with very low and extremely low birth weight.

6 tbl, 5 ex

FIELD: veterinary medicine.

SUBSTANCE: treatment is carried out with an aqueous solution of the preparation "Biopag-D" at a concentration of 4-2% by drifting animals through the baths with the solution having the immersion depth up to the carpal joint.

EFFECT: invention enables to treat efficiently and stress-free and prevent treatment of diseases of hooves and dew claws of animals.

3 cl, 5 dwg, 4 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: stimulating the excised liver regeneration is ensured by a 70% hepatectomy into a laboratory animal on the second day of the experiment. A liver regeneration stimulator is presented by L-norvaline administered intragastrically in a daily dose of 10.0 mg/kg every 46 hours for the first 7 days of the experiment.

EFFECT: method provides the effective stimulation of the excised liver regeneration evidenced by reducing the animals' lethality, improved hepatic microcirculation, reduced manifestation of cytolysis and enhanced synthetic function of the liver.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to therapeutic dentistry, and can be used for the local treatment of chronic gingivitis caused by tobacco smoking in young individuals. That is ensured by a preparatory procedure of luminal-dependent chemiluminescence of the oral fluid aiming at a maximum burst and a glow light sum. If the maximum burst falls within the range of 3.3 to 18.15 standard units, whereas the glow light sum ranges from 8.2 to 40 standard units, an antioxidant therapy is conducted by using a transverse gingival mucosa electrophoresis on 5% aqueous propolis by means of jaw electrodes in a tray at a current intensity of 0.5-1 mA and an exposure of 8-10 minutes. A polarity is alternated with a positive pole to be taken the first. The therapeutic course makes 4 procedures every second day. Colgate Propolis Toothpase and Mouthwash are used additionally during 30 days. If the maximum burst is from 0.8 to 1.24 standard units, whereas the glow light sum ranges from 3.34 to 7.5 standard units, a pro-oxidant therapy is required by using an exposure to magnetic infrared laser (MIL) light covering a projection of gums and generated by Optodan laser with a periodontal attachment The exposure parameters: 2-2,000 Hz in segments, 2 minutes per each segment, no more than 12 minutes per 1 procedure. The therapeutic course makes 4 procedures every second day. Parodontax Toothpase and Mouthwash are used additionally during 12 days.

EFFECT: method simplifies and reduces the length of the treatment in the given category of patients.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to oxazolopyramidine compounds of formula I, where A represents O; R1 is selected from phenyl or pyrimidine, which are optionally substituted with R11; R2 represents phenyl, which is optionally substituted wby 1-3 ring carbon atoms with similar or different substituents R22, R11 represents halogen; R22 is selected from hydroxy group, (C1-C4)-alkyl, which is optionallysubstituted with 1-3 atoms of fluorine, (C1-C4)-alkyloxy, (C1-C4)-alkyl-S(O)m-; m equals 2. Invention also relates to pharmaceutical composition, which contains formula I compounds, and to method of obtaining formula I compounds.

EFFECT: formula I compounds, intended for activation of EDG-1 receptor and applied for wound healing.

15 cl, 2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to oxazolopyramidine compounds of formula (I), where A represents O; X represents (C1-C6)-alkanediyl or (C1-C6)-alkanediyloxy, where oxygen atom of (C1-C6)-alkanediyloxy is bound to group R2; Y represents pyrrolidinyl; R1 represents (C1-C4)-alkyl; R2 represents phenylene, optionally substituted by one or two carbon atoms in ring with similar or different substituent R22; R3 is selected from group, which consists of cycloalkyl-CuH2u-, where u equals 1; radical of saturated 3-10-member monocyclic ring, phenyl or pyridyl, where ring radical is optionally substituted by one or two carbon atoms of ring with substituent R31; R4 represents hydrogen; R22 represents (C1-C4)-alkyl; R31 is selected from group, which consists of halogen and (C1-C4)-alkyl. Invention also relates to (S)-l-[2-(2,6-dimethyl-4-{5-[methyl-(3,3,3-trifluoropropyl)amino]-7-propoxyoxazolo[5,4-d]pyrimidine-2-yl}phenoxy)acetyl]pyrrolidine-2-carboxylic acid, pharmaceutical composition and to method of obtaining compounds of formula (I) .

EFFECT: compounds of formula (I), intended for activation of EDG-1 receptor and applied for wound healing.

16 cl, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to veterinary and can be applied in animal-breeding for stimulation of metabolic processes, and growth activity of calves. Medication for stimulation of metabolic processes and growth activity of calves includes succinic acid as energetic stimulator, with application of citric acid as activator of succinic acid, beetroot molasses as carbon component, and methionine and sodium chloride as stimulators of digestion system.

EFFECT: application of invention makes it possible to ensure expressed acceleration of growth energy in early postnatal period.

3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: cytoflavin is administered into laboratory animals (rats) daily immediately before overheating in an air laboratory thermostat at +40±1-2°C for 45 minutes. The preparation is administered intraperitoneally in a dose of 100 mg/kg of body weight for 14 days.

EFFECT: higher body adaptability by increasing antioxidant activity and reducing a rate of lipid peroxidation products accumulation with underlying thermal exposure.

4 tbl

FIELD: medicine.

SUBSTANCE: minor amputation of the foot with the further necrectomy is performed. After the application of an antimicrobial bandage and drainage, the wound is hermetised from the environment by the creation of a negative pressure above the wound in a combination with drug treatment. The reatment is performed in two steps. At the first step the wound with the antimicrobial bandage and drainage is first hermetised from above with an adhesive film, with the creation and support of the negative pressure not lower than 80 mm Hg. Urokinase 500000 U is additionally introduced daily intravenously by drop infusion per 100 ml of physiological solution, Vessel-Due-F in a dose of 600 LU per 100 ml of physiological solution and VAP 20 - alprostadil in a dose of 40 mcg per 100 ml of physiological solution. In addition Antistax in capsules is introduced to the patient. At the second stage active 24-hour vacuum aspiration with the change of the negative pressure from 10 to 80 mm Hg within a day is carried out. Additionally introduced is Vessel-Due-F in a dose of 1 capsule with 250 LU 2 times per day between meals and Antistax. At the first and second stages Antistax is introduced in a dose of 2 capsules in the morning 30-40 minutes before meal, daily. Duration of each stage constitutes not less than 7 days.

EFFECT: increase of the treatment efficiency due to the complete and timely purification of the wound from pathological exudates, elimination of the progression of the purulent-necrotic process, increase of the regenerative activity of tissues, activation of local immunity, recovery of microcirculation and oxygenation of the affected tissues.

2 cl, 2 ex

FIELD: medicine.

SUBSTANCE: method involves professional oral hygiene is carried out consisting in ultrasonic removal of supra- and subgingival dental deposits and polishing of supragingival teeth. Bite splinting and recovery of dentition integrity may be required. After dissecting a mucoperiosteal flap according to the known technique, an incision area is sanitated by means of a photodynamic therapy (PDT). The PDT is conducted with the use of a diode laser at wave length 660±5 nm and emitting power 0.5-1.0 Wt. The photosensitiser "Photoditasin" in the form of 0.5% gel is introduced by means of a cannula into dental gaps, under the dissected segments of the flap and onto the mucosal tissue for 5 minutes. The photosensitiser is washed out, and the gingival pockets are repeatedly exposed to laser light for 2-3 min in the same environment. Sterile osteoplastic material is introduced into bone defects, and the flap is sutured together.

EFFECT: effective cleansing of the surgical area, eliminating the periodontal inflammation, stimulating tissue osteogenesis and regeneration, stabilising the processes of bone tissue absorption of alveolar interdental septa and preserving the tissues.

2 cl, 1 ex

FIELD: medicine.

SUBSTANCE: to correct pathologic changes in the condition of viable offspring under a cytostatic impact the medication glutoxim is introduced to female rats in a dose of 50 mcg/kg 5 days before and 5 days after the introduction of the cytostatic medication vepesid. The latter is introduced once intravenously in a maximal tolerable dose, equal to 30 mg/kg. It has been established that glutoxim can be applied as means for the correction of pathologic changes in the viable offspring of rats, obtained from coupling 3 months after the cytostatic impact.

EFFECT: application of glutoxim as the means of corrective therapy makes it possible to increase efficiency and reduce its side effects.

6 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to haematology, and can be used for hormonal and radiation preparation to the following radiation chemotherapy in the treatment of patients with chronic lymphocytic leukaemia. For this purpose prednisolone is introduced in a dose of 0.9-1.1 mg/kg of weight per day. Exposure to radiation in the doses and regimens, conventional for the treatment of lymphoid tumours of a low-degree of malignancy is also carried out in the term from 72 to 168 hours after the beginning of prednisolone introduction. After obtaining 2/3-3/4 of the total dose of the radiation impact, reduction of the dose of introduced prednisolone is realised with its cancellation by the end of the radiation impact. Exposed to radiation are: involved into the leukemic process lymphatic organs from the group: lymph nodes, tonsils, spleen and liver.

EFFECT: method ensures an increased efficiency of chemotherapeutical programmes due to the preliminary impact, making it possible to reduce the involvement of organs into the leukemic process, increased sensitivity of leukemic lymphocytes to the following chemotherapeutic impact , with the reduction of a probability of development of complications, for instance, such as febrile neutropenia.

5 ex

Up!